"We believe it could take time for 10x to properly orient its Chromium commercial efforts." He has a buy rating on 10x ...

It believes Chromium will sustain “greater volume declines and/or pricing pressure than current management expectations, and thus perpetuate 10x Genomics’ margin degradation.” The bank sees ...

The Genomics Core houses a 10X Genomics Chromium iX which has the capacity to prepare GEMs for all standard 10X Genomics single cell pipelines: 3" scRNAseq single cell immune profiling fixed RNA ...

10x Genomics (NASDAQ:TXG) has built a reputation as a trailblazer in recent years, with cutting-edge single-cell and spatial technologies. The firm's Chromium, Visium and Xenium platforms have ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales ...

Additionally, the company’s Chromium installations exceeded expectations, further supporting the Buy rating. These factors together underpin the positive long-term outlook for 10x Genomics.

10x Genomics Inc is a life science technology ... The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others.

Specifically, the instrument and consumables revenues were higher than anticipated, with significant contributions from both Chromium and ... showcasing 10x Genomics’s ability to expand its ...

Our facility is equipped with state-of-art instruments, including the 10X Genomics Chromium X which enables high-throughput single cell gene expression profiling, 10X Genomics Xenium platform, and the ...

Increased cumulative instruments sold to more than 7,000 instruments as of the end of 2024, which includes over 5,800 Chromium instruments ... Co-founder and CEO of 10x Genomics.